CJC-1295 No DAC + Ipamorelin (10 mg)

At a Glance

CJC-1295 No DAC + Ipamorelin is a pre-blended lyophilised peptide combining 5 mg Modified GRF 1-29 (CJC-1295 No DAC) with 5 mg ipamorelin in a single 10 mg vial. The two act on distinct receptors in the same GH axis: GHRH-R via cAMP and GHS-R1a via calcium. The result is synergistic GH release that exceeds either peptide alone.[1]

• Reconstitute: Add 2.0 mL bacteriostatic water → 5.00 mg/mL total (2.50 mg/mL per component).
• Standard dose: 200 mcg total (100 mcg each) subcutaneous, once or twice daily. Pre-sleep injection is standard.
• Easy measuring: At 5.00 mg/mL on a U-100 syringe, 1 unit = 0.01 mL = 50 mcg total. A 200 mcg dose = 4 units / 0.04 mL.
• Storage: Lyophilised: refrigerate at 2–8 °C (freeze at −20 °C for long-term); reconstituted: refrigerate at 2–8 °C; use within 4 weeks.

Overview

• Composition: 5 mg CJC-1295 No DAC (Modified GRF 1-29) + 5 mg ipamorelin per 10 mg lyophilised vial.
• Goal: Synergistic stimulation of endogenous pulsatile GH release via dual receptor engagement on pituitary somatotrophs.[1]
• Schedule: Once or twice daily subcutaneous injection, on an empty stomach. Pre-sleep is the most common timing.
• Dose range: 100–200 mcg per peptide (200–400 mcg total) per injection.
• Reconstitution: 2.0 mL BAC water per 10 mg vial → 5.00 mg/mL total.
• Injection site: Abdomen, thigh, or upper arm; rotate daily.

What You'll Need

Plan based on a representative 8-week cycle at 200 mcg (4 units) once daily (56 injections, 11.2 mg total).

• CJC-1295 No DAC + Ipamorelin Vials (10 mg each): 11.2 mg needed ÷ 10 mg per vial → 2 vials (20 mg covers the cycle with buffer).
• Insulin Syringes (U-100, 0.3 mL / 30-unit preferred): 56 injections → 56 syringes.
• Bacteriostatic Water (10 mL bottles): 2.0 mL per vial → 1 × 10 mL bottle covers 5 vials.
• Alcohol Swabs: 2 per injection → 112 swabs per 8-week cycle.

How to Reconstitute

1. Allow the refrigerated lyophilised vial to reach room temperature (10–15 minutes).
2. Draw 2.0 mL bacteriostatic water with a sterile syringe.
3. Inject slowly down the inner vial wall; do not spray directly onto the powder.
4. Gently swirl or roll until fully dissolved. Do not shake. Solution should be clear and colourless.
5. Label with reconstitution date and both component names; refrigerate at 2–8 °C. Use within 4 weeks.

Dosing Schedule

Administer on an empty stomach; insulin from a recent meal suppresses GH secretion. Pre-sleep timing captures the nocturnal GH window; a morning injection (fasted, on waking) adds a second pulse. At the standard 200 mcg once daily, one 10 mg vial provides 50 days; at 200 mcg twice daily, 25 days.[1]

Protocol Details

• Week 1 (titration): 100 mcg total (2 units / 0.02 mL) once daily in the evening.
• Weeks 2+ (standard): 200 mcg total (4 units / 0.04 mL) once or twice daily.[1]
• Upper range: 400 mcg total (8 units / 0.08 mL) delivers ~200 mcg per peptide, used in some higher-dose research protocols.
• Cycle length: 8–12 weeks on, 4 weeks off. Rest periods support receptor sensitivity recovery.
• Injection site: Abdomen, thigh, or upper arm; rotate daily to minimise site reactions.

Storage

• Lyophilised: Refrigerate at 2–8 °C (35–46 °F); freeze at −20 °C for storage beyond 3 months. Protect from light.
• Reconstituted: Refrigerate at 2–8 °C. Avoid freeze-thaw cycles. Use within 4 weeks.
• Appearance: Clear, colourless solution. Discard if cloudy, coloured, or particulate.

How CJC-1295 No DAC + Ipamorelin Works

The two peptides act at different receptors on the same pituitary cell.

CJC-1295 No DAC (Modified GRF 1-29) is a 29-amino acid analogue of endogenous GHRH with four substitutions (D-Ala², Gln⁸, Ala¹⁵, Leu²⁷) that confer resistance to DPP-IV cleavage.[2] It binds the GHRH receptor (GHRH-R) on pituitary somatotrophs, activating Gs/adenylyl cyclase/cAMP/PKA to drive GH synthesis and release. Half-life: ~30 minutes, a clean pulse aligned with natural pulsatility, without the prolonged albumin-binding extension of the DAC form. CAS 863288-34-0. MW 3367.95.

Ipamorelin binds GHS-R1a (the ghrelin receptor) on the same cells, coupling through Gαq → PLC → IP₃ → calcium release to trigger a separate secretory cascade.[3] CAS 170851-70-4. MW 711.85.

When both act simultaneously, the cAMP signal from GHRH-R and the calcium signal from GHS-R1a converge as mutually reinforcing secretory inputs. The result is a GH pulse larger than either peptide produces alone.[1]

Good to Know

• Both peptides have a half-life of ~30 minutes. Timing relative to sleep and fasting matters more than with longer-acting analogues.
• CJC-1295 No DAC (Modified GRF 1-29) is a distinct compound from CJC-1295 with DAC. The DAC cysteine modification binds albumin and extends half-life to 6–8 days, a fundamentally different pharmacokinetic profile. This vial contains the No-DAC form only.
• Administer on an empty stomach; insulin suppresses the GH pulse.
• WADA status: Both peptides are S2-class non-approved peptides. Athletes under anti-doping programmes must not use this blend.
• For background on the mechanism, evidence, and research applications, see What Is CJC-1295 + Ipamorelin Blend?.

Tips for Best Results

• Inject on an empty stomach, at least 1–2 hours after the last meal. Pre-sleep is the primary timing in most research protocols.
• A morning injection (fasted, immediately on waking) adds a second pulse without conflicting with the nocturnal GH window.
• Pair with adequate protein (1.2–1.6 g/kg) and consistent sleep (7–9 hours); GH/IGF-1 elevation works in concert with recovery.
• Avoid eating for 30–60 minutes post-injection.
• Track injection sites and rotate; note any local reactions on the first few injections.

Injection Tips

• Clean the vial stopper and injection site with separate alcohol swabs; allow both to air-dry fully before proceeding.
• Using a 29–31 gauge insulin syringe (5/16″ to 1/2″ needle), draw the calculated dose precisely.
• Pinch a fold of skin and insert the needle at 45° into subcutaneous fat (90° is acceptable with a short needle into a well-pinched fold).
• Inject slowly over 2–3 seconds; do not aspirate. Withdraw the needle, apply gentle pressure, and do not rub the site.
• Rotate injection sites (abdomen, thighs, upper arms) and dispose of each syringe in a sharps container immediately after use.[4]